{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0306","value":"0.0214"},{"groupId":"OG001","spread":"0.0301","value":"0.0167"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"Change from baseline in bone mineral density (BMD) will be assessed by dual energy x-ray absorptiometry scans at baseline and the EOT visit","dispersionType":"Standard Deviation","groups":[{"description":"bortezomib (Velcade) 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles","id":"OG000","title":"Bortezomib"},{"description":"no treatment, observation only","id":"OG001","title":"Non-treated Control"}],"paramType":"MEAN","populationDescription":"ITT analysis:13 patients in the bortezomib group and 14 patients in the non-treated control group did not have values at the 2 timepoints to allow calculation of the parameter","reportingStatus":"POSTED","timeFrame":"at screening (i.e. between 14 and 1 days prior to start of treatment) and at end of treatment (EOT), i.e. 24 weeks after randomization or until start of alternative MMY therapy, if earlier","title":"Change From Baseline in Bone Mineral Density (BMD) in the Spine at End of Treatment (EOT)","type":"PRIMARY","unitOfMeasure":"g/mm2"}